IOMX-0675 / iOmx Therap - LARVOL DELTA

IOMX-0675, a LILRB1/LILRB2 cross-specific antibody that repolarizes the tumor microenvironment to drive potent anti-tumor activity (AACR 2025) - "IOMX-0675 demonstrates robust reprogramming of the immunosuppressive myeloid compartment and restores cytotoxic T cell activity within the tumor microenvironment, both in vitro and in vivo. Its differentiated binding profile positions IOMX-0675 as a best-in-class therapeutic candidate with the potential to maximize anti-tumor efficacy and address significant unmet medical needs for patients."

Biomarker • Tumor microenvironment • Melanoma • Oncology • Solid Tumor • CD34 • LILRB1

IOMX-0675, a LILRB1/LILRB2 cross-specific antibody that reprograms the tumor microenvironment to trigger potent anti-tumor activity (ITOC 2025) - "IOMX-0675 demonstrates robust reprogramming of the immunosuppressive myeloid compartment and restores cytotoxic T cell activity within the tumor microenvironment, both in vitro and in vivo. Its differentiated binding profile positions IOMX-0675 as a best-in-class therapeutic candidate with the potential to maximize anti-tumor efficacy and address significant unmet medical needs for patients."

Biomarker • IO biomarker • Tumor microenvironment • Melanoma • Oncology • Solid Tumor • CD34 • LILRB1 • LILRB2

IOMX-0675, a cross-specific antibody selectively inhibiting LILRB1 and LILRB2, repolarizes immunosuppressive myeloid cells and activates cytotoxic T cells leading to potent tumor cell killing (SITC 2024) - "The unique binding profile of IOMX-0675 provides best-in-class potential for a dual-targeting myeloid checkpoint inhibitor that may maximize anti-tumor efficacy in patients across various solid cancer indications. A first-in­-human clinical study is in preparation."

Tumor cell • Oncology • Solid Tumor • LILRB1 • LILRB2

IOMX-0675, a cross-specific antibody selectively inhibiting LILRB1 and LILRB2, repolarizes immunosuppressive myeloid cells and activates T cells (EORTC-NCI-AACR 2024) - "We discovered that IOMX-0675, a cross-specific antibody antagonizing both LILRB1 and LILRB2 with high selectivity, exhibits potent reprogramming of the immunosuppressive myeloid compartment and restores cytotoxic T cell activity in the TME. The differential binding profile of IOMX-0675 provides best-in-class potential and may maximize anti-tumor efficacy across various solid cancer indications."

Melanoma • Oncology • Solid Tumor • CD34 • LILRB1

IOMX-0675, a cross-specific antibody selectively inhibiting LILRB1 and LILRB2, effectively repolarizes immunosuppressive myeloid cells and activates cytotoxic T cells leading to potent tumor cell killing (CRI-ENCI-AACR ICIC 2024) - "IOMX-0675 exhibits potent reprogramming capacity of the immunosuppressive myeloid compartment and restores cytotoxic T cell activity in the tumor microenvironment in vitro and in vivo. The unique binding profile of IOMX-0675 provides best-in-class potential for a dual-targeting myeloid checkpoint inhibitor that may maximize anti-tumor efficacy in patients across a variety of solid cancer indications."

Tumor cell • Melanoma • Oncology • Solid Tumor • CD34 • LILRB1 • LILRB2

IOMX-0675, a LILRB1 and LILRB2 cross-specific antibody, effectively repolarizes immunosuppressive myeloid cells and activates T cells leading to potent tumor cell killing (CIMT 2024) - "IOMX-0675 exhibits potent reprogramming capacity of the immunosuppressive myeloid compartment and restores cytotoxic T cell activity in the tumor microenvironment. The unique binding profile of IOMX-0675 provides best-in-class potential for a dual-targeting myeloid checkpoint inhibitor that may maximize anti- tumor efficacy in patients across a variety of solid cancer indications."

Tumor cell • Oncology • Solid Tumor • CD34 • LILRB1 • LILRB2

IOMX-0675, a LILRB1 and LILRB2 cross-specific antibody, effectively repolarizes immunosuppressive myeloid cells and activates T cells leading to potent tumor cell killing (AACR 2024) - "Negligible binding to immune-activating LILR family members by IOMX-0675 could unleash full anti-tumor activity. The differential binding profile of IOMX-0675 provides best-in-class potential and may maximize anti-tumor efficacy for the benefit of patients with high-unmet medical need, who are resistant to T cell checkpoint blockade."

Tumor cell • Oncology • Solid Tumor • LILRB1 • LILRB2

iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024 (GlobeNewswire) - "iOmx Therapeutics AG...announces that it will present new data on its lead I/O drug candidates...at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024....The antibody IOMX-0675 targets the two most potent immunosuppressive members of this family, namely LILRB1/2....Dual targeting of these receptors on myeloid cells results in a pronounced anti-tumor immune response, retuning the tumor microenvironment and activating T cells against cancer cells. The specificity and dual approach of IOMX-0675 indicate its potential as a promising candidate to provide a new treatment avenue for patients with limited options due to resistance to current therapies."

Preclinical • Oncology